focus -WSS

focus

author：focus 2025-09-30 11:07:13 - browse：5

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Ancient Greek ideas underpin modern concepts of pregnancy

explore

WSS

Drug companies' payments and gifts affect physicians' prescribing

Longer MASH drug regimen improved liver, Akero study finds

Florida health officials providing scant details on measles cases

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Scientists uncover potential path to treating deadly childhood tumor

$1 billion proposal to grow Boston, Massachusetts biotech

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Drug repurposing or repositioning? The language matters

$1 billion proposal to grow Boston, Massachusetts biotech

Wildfire smoke exposes gaps in outdoor worker protections

Pancreatic cancer is often deadly, but new discoveries are raising hope

The high cost of giving birth even with insurance

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Novavax promises a turnaround & Lilly roils the obesity market

Medicare drug price negotiation continues, as pharma counteroffers

Cancer drug shortages should be causing more outrage

Young boy dies in trial for Pfizer Duchenne gene therapy

knowledge

Gut bacteria may contribute to kidney autoimmunity, study finds

Longer MASH drug regimen improved liver, Akero study finds

Pancreatic cancer is often deadly, but new discoveries are raising hope

Florida health officials providing scant details on measles cases

Scientists uncover potential path to treating deadly childhood tumor

Florida health officials providing scant details on measles cases

hotspot

explore

Wikipedia

hotspot